Skip to main navigation Skip to search Skip to main content

Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands–A Nationwide Overview From 2008 Until 2022

  • Jelle Evers*
  • , M. J.C. van der Sangen
  • , M. C. van Maaren
  • , J. H. Maduro
  • , L. Strobbe
  • , M. J. Aarts
  • , M. C.W.M. Bloemers
  • , J. Wesseling
  • , D. H.J.G. van den Bongard
  • , H. Struikmans
  • , S. Siesling
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

31 Downloads (Pure)

Abstract

Aims: Ductal Carcinoma In Situ (DCIS) treated by breast-conserving surgery followed by radiotherapy aims to decrease the probability of locally recurrent disease. The role of whole breast irradiation, specifically in DCIS having low recurrence risk and low risk of becoming invasive, is increasingly debated. Also, the added value of applying boost irradiation in DCIS has been questioned. Hence, we evaluated the nationwide radiotherapy use in DCIS treatment in the Netherlands. Materials and Methods: Women diagnosed with DCIS in 2008–2022 were identified in the Netherlands Cancer Registry. Their primary treatment was presented over time and for age groups, stratified for DCIS grade I-II and III. Factors associated with radiotherapy use after breast-conserving surgery and boost irradiation use in whole breast irradiation after breast-conserving surgery were identified. Results: In women with DCIS grade I-II (N = 16,653), the use of breast-conserving surgery without radiotherapy increased from ∼11% in 2008–2013 to ∼26% in 2017–2022. Furthermore, post-breast-conserving surgery radiotherapy increasingly concerned whole breast irradiation without a boost or partial breast irradiation. Moreover, surgery was omitted more often in recent years (30% in 2022). In DCIS grade III (N = 13,534), the use of breast-conserving surgery without radiotherapy only slightly increased in the most recent years in older patients, while boost irradiation was increasingly omitted. Whole breast irradiation and boost irradiation following breast-conserving surgery were more often applied in case of a higher risk of recurrences: young age, larger lesions, or irradical resection. Variation was observed for hospital-characteristics but not for regions. Conclusion: In DCIS, the process of omitting breast irradiation after breast-conserving surgery is clearly ongoing. Boost irradiation was administered less frequently. Furthermore, the use of partial breast irradiation was introduced in recent years. These effects are more prominent in older women and those with grade I-II DCIS.

Original languageEnglish
Article number103740
Number of pages12
JournalClinical oncology
Volume38
Early online date16 Dec 2024
DOIs
Publication statusPublished - Feb 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • 2025 OA procedure
  • UT-Hybrid-D
  • Ductal Carcinoma in-Situ
  • epidemiology
  • radiotherapy
  • Boost irradiation
  • breast-conserving therapy

Fingerprint

Dive into the research topics of 'Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands–A Nationwide Overview From 2008 Until 2022'. Together they form a unique fingerprint.

Cite this